DEF: Cryoport 2026 Proxy Statement Overview

Cryoport, Inc. announces its 2026 Annual Meeting of Stockholders to be held virtually on June 5, 2026, to address director elections, executive compensation, and equity plan amendments.

Summary

• Full-year 2025 revenue reached $176.2 million, a 12% year-over-year increase, exceeding guidance.
• Commercial Cell & Gene Therapy (CGT) revenue grew 29% to $33.4 million, while clinical trial revenue grew 14% to $47.1 million.
• Life Sciences Services segment revenue was $96.5 million, representing 55% of total revenue.
• Life Sciences Products revenue reached $79.7 million, a 7% increase.
• The company established the Enterprise Technology Group (ETG) to integrate AI and digital capabilities.
• 2026 revenue guidance is forecasted between $190 million and $194 million.
• The company is seeking stockholder approval to amend the 2018 Omnibus Equity Incentive Plan to increase authorized shares by 4,275,000.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, reflecting strong revenue growth and a clear strategic roadmap, though tempered by the lack of current profitability and the request for additional equity dilution.

Positives

• Revenue of $176.2 million exceeded the high end of guidance.
• Strong growth in core CGT markets, supporting 760 clinical trials and 20 commercial therapies.
• Strategic partnership formed with DHL Group, including the divestiture of CRYOPDP.
• Successful expansion of global supply chain network, including new facilities in Paris and Belgium.
• Maintained a disciplined equity usage rate between 1.63% and 2.42% over the past three years.

Negatives

• Reported a net loss of $5.78 million for 2025.
• Adjusted EBITDA for 2025 was negative $5.8 million.
• Continued reliance on equity-based compensation, with a proposal to increase authorized shares by 4.275 million, potentially increasing dilution.
• The company has not yet achieved profitability.

Risks

• Exposure to changing economic and geopolitical conditions.
• Supply chain constraints and inflationary pressures.
• Foreign currency fluctuations impacting financial results.
• Market acceptance risks for new products and services.
• Technical development risks associated with new technology platforms.
• Potential disruption from the CRYOPDP divestiture and integration of new business units.

Future Outlook

The company forecasts 2026 revenue of $190 million to $194 million, anticipating nine new therapy approvals and thirteen BLA/MAA filings in 2026.

Management Comments

• 2025 was a year of strong progress for Cryoport, advancing our mission of supporting life and health.
• We believe we enter 2026 with a strong balance sheet and a clear pathway to future profitability.
• ETG will enable Cryoport to scale faster, differentiate more effectively, and build the future of intelligent temperature-controlled supply chain management.

Industry Context

StockSavvy.ai notes that Cryoport continues to solidify its position as a critical infrastructure provider for the high-growth Cell & Gene Therapy sector, leveraging strategic partnerships and digital transformation to maintain market leadership despite broader macroeconomic headwinds.

Comparison to Industry Standards

• Cryoport supports approximately 70% of all CGT industry clinical trials, indicating a dominant market share.
• The company maintains a disciplined equity usage rate compared to industry peers, as evaluated by independent compensation consultants.
• The company's focus on ISO certifications (ISO 21973:2020, ISO 9001:2015) aligns with global quality standards for life sciences logistics.

Corporate Governance

Related Party Transactions

• Ongoing relationship with Blackstone entities regarding Series C Preferred Stock, including dividend payments and board representation rights.

Stakeholder Impact

• Shareholders are asked to vote on key governance and compensation matters.
• Employees benefit from the proposed expansion of the equity incentive plan.
• Clients benefit from continued investment in global supply chain infrastructure and digital capabilities.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 5, 2026.
• Conduct shareholder vote on director elections, auditor ratification, executive compensation, and equity plan amendment.
• File Form S-8 registration statement if the equity plan amendment is approved.

Key Dates

Recommendation

The company is showing strong top-line growth and market leadership in a critical sector, but the lack of profitability and the ongoing need for share dilution to fund operations suggest a cautious 'hold' until a clearer path to positive earnings is demonstrated.

Keywords

Cryoport, Cell and Gene Therapy, Supply Chain, Life Sciences, Proxy Statement, Biologistics, Equity Incentive Plan